InnovaRx Innova Health Strategies

L49.2

Exfoliation due to erythematous condition involving 20-29 percent of body surface

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 12 never code together
L49-L54block
Excludes1
L00-L99chapter
Excludes2
  • certain conditions originating in the perinatal period (P04-P96)P04-P96
  • certain infectious and parasitic diseases (A00-B99)A00-B99
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations, and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • lipomelanotic reticulosis (I89.8)I89.8
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94
  • systemic connective tissue disorders (M30-M36)M30-M36
  • viral warts (B07.-)B07.-

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 6
L49code
Code first
  • erythematous condition causing exfoliation, such as:
  • Ritter's disease (L00)L00
  • (Staphylococcal) scalded skin syndrome (L00)L00
  • Stevens-Johnson syndrome (L51.1)L51.1
  • Stevens-Johnson syndrome-toxic epidermal necrolysis overlap syndrome (L51.3)L51.3
  • Toxic epidermal necrolysis (L51.2)L51.2
Index entries leading here 1
  • Exfoliation
    • due to erythematous conditions according to extent of body surface involved L49.0
      • 20-29 percent of body surface L49.2
Alongside this code 9 same parent — L49
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
L49
Block
L49-L54
Siblings
9

Present FY2024–FY2027.